Fibrocell Science Quick Ratio (FCSC) starting from the third quarter 2019 to third quarter 2018, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Fibrocell Science, Inc.  (FCSC)

Fibrocell Science's Quick Ratio

FCSC's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Regardless of the sequential decrease in Current Liabilities, during the third quarter 2019, Quick Ratio deteriorated to 1.85 below Fibrocell Science's average Quick Ratio.

Within Major Pharmaceutical Preparations industry 334 other companies have achieved higher Quick Ratio than Fibrocell Science in third quarter 2019. While Quick Ratio total ranking has improved so far during the Q3 2019 to 1250, from total ranking in the second quarter 2019 at 1263.

Explain Quick Ratio?
How much Cash & cash equivalents FCSC´s has?
What are FCSC´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

FCSC Quick Ratio (Sep 30 2019)
Q3		 (Jun 30 2019)
Q2		 (Mar 31 2019)
Q1		 (Dec 31 2018)
Q4		 (Sep 30 2018)
Q3
Y / Y Current Liabilities Change 102.43 % 246.73 % 84.9 % -50.92 % -47.76 %
Y / Y Cash & cash equivalent Change -57.99 % -11.1 % -7.2 % -17.15 % 35.26 %
Quick Ratio MRQ 1.85 1.93 3.25 6.64 8.9
FCSC's Total Ranking # 1250 # 1263 # 864 # 480 # 359
Seq. Current Liabilities Change -48.37 % 103.53 % 60.64 % 19.93 % -11.57 %
Seq. Cash & cash equivalent Change -50.6 % 21 % -21.54 % -10.43 % 4.55 %



Quick Ratio third quarter 2019 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 335
Healthcare Sector # 549
Overall Market # 1250


Quick Ratio Statistics
High Average Low
22.29 7.17 0.02
(Mar 31 2014)  




Financial Statements
Fibrocell Science's Current Liabilities $ 4 Millions Visit FCSC's Balance sheet
Fibrocell Science's Cash & cash equivalent $ 7 Millions Visit FCSC's Balance sheet
Source of FCSC's Sales Visit FCSC's Sales by Geography


Cumulative Fibrocell Science's Quick Ratio

FCSC's Quick Ratio for the trailling 12 Months

FCSC Quick Ratio

 (Sep 30 2019)
12 Months		 (Jun 30 2019)
12 Months		 (Mar 31 2019)
12 Months		 (Dec 31 2018)
12 Months		 (Sep 30 2018)
12 Months
Y / Y Current Liabilities TTM Growth 61.52 % 23.22 % -27.87 % -44.52 % -20.75 %
Y / Y Cash & cash equivalent TTM Growth -24.4 % -2.42 % -0.29 % -11.62 % -7.22 %
Quick Ratio TTM 2.81 3.81 6.02 7.34 6.01
Total Ranking TTM # 4470 # 4292 # 237 # 4034 # 4142
Seq. Current Liabilities TTM Growth 12.73 % 53.08 % 20.23 % -22.15 % -14 %
Seq. Cash & cash equivalent TTM Growth -16.82 % -2.99 % -1.51 % -4.89 % 7.38 %

Quick ratio ranking by company, industry and sector >> Back to FCSC Financial Strength Comparisons >> Go to Compare FCSC Quick Ratio to its Competitors

On the trailing twelve months basis Due to drop in Current Liabilities in the Q3 2019 to $3.67 millions, cumulative Quick Ratio decreased to 2.81 below the Fibrocell Science, Inc. average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 456 other companies have achieved higher Quick Ratio than Fibrocell Science. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2019 from 4292 to 4470.

Explain Quick Ratio?
How much Cash & cash equivalents FCSC´s has?
What are FCSC´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 457
Healthcare Sector # 885
Within the Market # 4470


trailing twelve months Quick Ratio Statistics
High Average Low
16.19 7.24 2.81
(Sep 30 2014)   (Sep 30 2019)




Companies with similar Quick Ratio in the quarter ending Sep 30 2019, within Major Pharmaceutical Preparations Industry Quick RatioSep 30 2019 MRQ Cash & cash equivalentSep 30 2019 MRQ Current Liabilities
Larimar Therapeutics Inc   5.02 $ 82.006  Millions$ 16.339  Millions
Mersana Therapeutics inc   5.00 $ 112.002  Millions$ 22.384  Millions
Quoin Pharmaceuticals Ltd   4.98 $ 5.239  Millions$ 1.052  Millions
Sarepta Therapeutics Inc   4.93 $ 1,048.892  Millions$ 212.553  Millions
Bioxcel Therapeutics Inc   4.91 $ 40.252  Millions$ 8.206  Millions
Panbela Therapeutics Inc   4.90 $ 3.377  Millions$ 0.689  Millions
Agios Pharmaceuticals Inc   4.89 $ 451.897  Millions$ 92.432  Millions
Alnylam Pharmaceuticals Inc   4.88 $ 1,721.058  Millions$ 352.864  Millions
Lisata Therapeutics Inc   4.88 $ 29.161  Millions$ 5.979  Millions
Tff Pharmaceuticals Inc  4.82 $ 10.551  Millions$ 2.188  Millions
Syros Pharmaceuticals Inc   4.82 $ 108.776  Millions$ 22.570  Millions
Inovio Pharmaceuticals Inc   4.80 $ 93.799  Millions$ 19.547  Millions
Pds Biotechnology Corp  4.78 $ 17.407  Millions$ 3.644  Millions
Urogen Pharma Ltd   4.76 $ 66.998  Millions$ 14.088  Millions
Genprex Inc   4.74 $ 2.548  Millions$ 0.537  Millions
Aimmune Therapeutics Inc   4.72 $ 195.470  Millions$ 41.442  Millions
Beone Medicines Ltd   4.69 $ 1,246.190  Millions$ 265.734  Millions
Enlivex Therapeutics Ltd  4.65 $ 12.008  Millions$ 2.580  Millions
Marinus Pharmaceuticals Inc   4.65 $ 39.889  Millions$ 8.571  Millions
Flexion Therapeutics Inc   4.65 $ 175.760  Millions$ 37.790  Millions
Protagonist Therapeutics inc   4.47 $ 137.692  Millions$ 30.776  Millions
Cellectar Biosciences Inc   4.47 $ 13.302  Millions$ 2.978  Millions
Prophase Labs Inc   4.41 $ 4.728  Millions$ 1.073  Millions
Merrimack Pharmaceuticals Inc  4.40 $ 20.858  Millions$ 4.739  Millions
Immunic Inc   4.33 $ 30.460  Millions$ 7.036  Millions
Cytomx Therapeutics Inc   4.28 $ 325.713  Millions$ 76.126  Millions
Phio Pharmaceuticals Corp  4.28 $ 8.709  Millions$ 2.036  Millions
Catalyst Pharmaceuticals Inc   4.26 $ 76.545  Millions$ 17.982  Millions
Esperion Therapeutics Inc   4.24 $ 243.861  Millions$ 57.518  Millions
Tonix Pharmaceuticals Holding Corp   4.24 $ 10.024  Millions$ 2.366  Millions

Date modified: 2026-09-08T15:09:43+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.